FindTrial
Sign In

Comparison of different usage of tranexamic acid for blood loss reduction and incerased pain after primary total hip arthroplasty

Comparison of different usage of tranexamic acid for blood loss reduction and incerased pain after primary total hip arthroplasty

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052396
Enrollment
Unknown
Registered
2021-10-24
Start date
2021-11-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bloos loss for Total Hip Arthroplasty

Interventions

Oral TXA group:Oral TXA
Intravenous TXA group: Intravenous TXA

Sponsors

Yixing People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who underwent THA surgery from January 2021 to December 2022.

Exclusion criteria

Exclusion criteria: 1. History of renal failure; 2. History of kidney transplantation; 3. History of cardiovascular and cerebrovascular embolism in the past 1 year; 4. Stent implantation history in the past 1 year; 5. History of deep vein thrombosis or pulmonary embolism; 6. Pregnant or breastfeeding women; 7. Poor compliance.

Design outcomes

Primary

MeasureTime frame
hemoglobin level;Pain score;blood transfusion;Deep venous thrombosis;pulmonary embolism;Harris Hip Score;—

Countries

China

Contacts

Public ContactShen Lei

Yixing People's Hospital

slxytbien@163.com+86 13773826574

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026